<DOC>
	<DOCNO>NCT00824447</DOCNO>
	<brief_summary>This study design give additional information efficacy , safety local effect ( tolerability ) dose sublingual immunotherapy administer day , second grass pollen season .</brief_summary>
	<brief_title>Long-term Efficacy Safety Study With Oralgen Grass Pollen</brief_title>
	<detailed_description>Allergy one common chronic disease . Allergies grass , weed , tree pollen characteristically result seasonal rhinitis symptom commonly term hay fever . The risk develop asthma note high patient rhinitis among general population ( 10 % versus 3.6 % ) , confirm fact rhinitis often first step natural history asthma . Although several drug effectively manage symptom allergic rhinitis , conjunctivitis asthma , represent etiopathogenic treatment consider disease , prevent reappearance symptoms end treatment . Immunotherapy generally consider appropriate patient rhinitis symptom control optimal medication regimen avoidance allergen . At present , specific immunotherapy therapy available act main cause allergic reaction modify down-regulating immune response . Allergen immunotherapy administration gradually increase quantity allergen vaccine ( extract ) allergic subject , reach maintenance dose , effective reducing symptom associate exposure causative allergen .</detailed_description>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Patients meet exclusion criterion study AB0602 successfully finish study . Patients give write consent participate study . Patients willing comply protocol understand information give . Female patient childbearing potential eligible sexually active use medically accept contraceptive method . Negative urine pregnancy test female end previous study . Pregnancy , breastfeed / lactation sexually active woman childbearing potential use medically accept contraceptive method . Patients noncompliant study AB0602 . Patients past current disease , judge investigator , may affect patient 's participation outcome study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>51 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>randomise</keyword>
	<keyword>double-blind</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>long-term efficacy safety</keyword>
	<keyword>OralgenÂ® Grass Pollen</keyword>
	<keyword>allergic rhinoconjunctivitis</keyword>
	<keyword>Allergy</keyword>
	<keyword>Rhinoconjunctivitis</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Grass pollen extract</keyword>
</DOC>